Study of PGBD3: Potential Drug Target Or Biomarker (G267004)

Target Name: PGBD3

NCBI ID: G267004

PGBD3

Study of PGBD3: Potential Drug Target Or Biomarker

PGBD3, also known as CSB-PGBD3 fusion protein, is a protein that is being studied for its potential as a drug target or biomarker. PGBD3 is a fusion protein that is made by combining two proteins, CSB (citrate synthase subunit B) and PGBD3 (pyruvate dehydrogenase subunit 3), to create a protein that is able to catalyze the chemical reaction that is the first step in the citric acid cycle, also known as the Krebs cycle or TCA cycle.

The citric acid cycle is a process that occurs in all cells and is responsible for producing energy in the form of ATP. It is also involved in the production of molecules that are used for signaling and signaling systems, such as nitric oxide. PGBD3 is thought to play a key role in the citric acid cycle and may be a drug target or biomarker because of its involvement in this process.

One of the key reasons why PGBD3 is being studied as a potential drug target is its involvement in the production of reactive oxygen species (ROS), which can cause damage to cells and contribute to a variety of diseases, including cancer. ROS are produced by processes that are similar to the citric acid cycle, and PGBD3 has been shown to play a role in the production of ROS.

In addition to its involvement in the production of ROS, PGBD3 is also thought to be involved in the regulation of cellular processes that are important for cell survival. For example, PGBD3 has been shown to play a role in the production of autophagy, a process that is important for the survival and growth of cells.

Another potential reason why PGBD3 is being studied as a potential drug target is its involvement in the production of molecules that are involved in the development and progression of cancer. For example, PGBD3 has been shown to play a role in the production of molecules that can promote the growth and survival of cancer cells.

In addition to its potential as a drug target or biomarker, PGBD3 is also being studied for its potential as a diagnostic tool. For example, PGBD3 has been shown to be expressed in a variety of tissues and fluids, including blood, saliva, and urine. This suggests that it may be a useful biomarker for certain types of cancer.

Overall, PGBD3 is a protein that is being studied for its potential as a drug target or biomarker due to its involvement in the citric acid cycle and its production of ROS. Further research is needed to fully understand its role in these processes and its potential as a diagnostic tool.

Protein Name: PiggyBac Transposable Element Derived 3

Functions: Binds in vitro to PGBD3-related transposable elements, called MER85s; these non-autonomous 140 bp elements are characterized by the presence of PGBD3 terminal inverted repeats and the absence of internal transposase ORF

The "PGBD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGBD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets